TopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Tazarotene

CAS 118292-40-3

Tazarotene (CAS 118292-40-3) is a Phase 4 pharmaceutical compound with 3 bioactivity targets and 133 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
7
SOURCE DrugCentral
Adverse signals
133
SOURCE IUPHAR/BPS
PubMed IDs
1
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Tazarotene
CAS Number
118292-40-3
UNII
81BDR9Y8PS
InChIKey
OGQICQVSFDPSEI-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1657
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Tazorac
dosed ingredientnatural producttherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1657 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 7 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 22038.117567567566 nM 74 -
- Potency 14110.235714285716 nM 14 -
- EC50 34.6 nM 6 -
- IC50 14367.539999999999 nM 2 -
Retinoic acid receptor alpha
Nuclear hormone receptor
 EC50 7.2 - Homo sapiens
Retinoic acid receptor beta
Nuclear hormone receptor
 EC50 9.1 - Homo sapiens
Retinoic acid receptor gamma
Nuclear hormone receptor
 EC50 7.4 - Homo sapiens
SOURCE DrugCentral 6 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Application site discolouration 12 73.193 10059005
Application site erythema 13 57.321 10003041
Skin depigmentation 10 56.619 10040825
Application site pain 11 47.996 10003051
Skin exfoliation 17 41.883 10040844
Post inflammatory pigmentation change 6 34.629 10036229

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 3 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
Retinoic acid receptor-α
RARA
 Agonist 7.199999809265137 pEC50 19058965
Retinoic acid receptor-β
RARB
 Agonist 9.100000381469727 pEC50 19058965
Retinoic acid receptor-γ
RARG
 Agonist 7.400000095367432 pEC50 19058965
SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
TAZAROTENE 83947 SU MTHSPL
tazarotene 83947 SU MTHSPL
tazarotene 83947 IN RXNORM
Tazorac 220181 BN RXNORM
SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Acne tazarotene LLT C0702166
Acne tazarotene PT C0702166
Application site dryness tazarotene LLT C0877098
Application site dryness tazarotene PT C0877098
Application site erythema tazarotene LLT C0853700
Application site erythema tazarotene PT C0853700
Application site exfoliation tazarotene LLT C1610049
Application site exfoliation tazarotene PT C1610049
Application site irritation tazarotene LLT C0521490
Application site irritation tazarotene PT C0521490
Application site pain tazarotene LLT C0521491
Application site pain tazarotene PT C0521491
Application site pruritus tazarotene LLT C0853714
Application site pruritus tazarotene PT C0853714
Application site rash tazarotene LLT C0521495
Application site rash tazarotene PT C0521495
Blister tazarotene LLT C0005758
Blister tazarotene PT C0005758
Blood triglycerides increased tazarotene PT C0853692
Burning sensation tazarotene LLT C0085624
Burning sensation tazarotene PT C0085624
Cheilitis tazarotene LLT C0007971
Cheilitis tazarotene PT C0007971
Dermatitis tazarotene LLT C0011603
Dermatitis tazarotene PT C0011603
Dermatitis tazarotene PT C0011603
Dermatitis bullous tazarotene PT C0085932
Dermatitis contact tazarotene LLT C0011616
Dermatitis contact tazarotene PT C0011616
Dermatitis contact tazarotene PT C0011616
Dermatitis irritant contact tazarotene LLT C0162823
Discomfort tazarotene LLT C0234215
Discomfort tazarotene PT C0234215
Dry skin tazarotene LLT C0151908
Dry skin tazarotene PT C0151908
Eczema tazarotene LLT C0013595
Eczema tazarotene PT C0013595
Erythema tazarotene LLT C0041834
Erythema tazarotene PT C0041834
Facial pain tazarotene LLT C0015468
Facial pain tazarotene PT C0015468
Haemoglobin tazarotene PT C0518015
Haemorrhage tazarotene LLT C0019080
Haemorrhage tazarotene PT C0019080
Hypertriglyceridaemia tazarotene LLT C0020557
Hypertriglyceridaemia tazarotene PT C0020557
Impetigo tazarotene LLT C0021099
Impetigo tazarotene PT C0021099
Inflammation tazarotene LLT C0021368
Inflammation tazarotene PT C0021368
Instillation site pain tazarotene PT C0858797
Leukoderma tazarotene LLT C0162835
Leukoderma tazarotene PT C0162835
Localised oedema tazarotene LLT C0013609
Localised oedema tazarotene PT C0013609
Localized exfoliation tazarotene LLT C0520893
Oedema tazarotene LLT C0013604
Oedema tazarotene PT C0013604
Oedema peripheral tazarotene LLT C0085649
Oedema peripheral tazarotene PT C0085649
Pain tazarotene LLT C0030193
Pain tazarotene PT C0030193
Pain tazarotene PT C0030193
Pain of skin tazarotene LLT C0241136
Pain of skin tazarotene PT C0241136
Photosensitivity reaction tazarotene PT C0162830
Phototoxicity tazarotene LLT C1527358
Pruritus tazarotene LLT C0033774
Pruritus tazarotene PT C0033774
Rash tazarotene LLT C0015230
Rash tazarotene PT C0015230
Sensitisation tazarotene LLT C1325847
Sensitisation tazarotene PT C1325847
Skin discolouration tazarotene LLT C0151907
Skin discolouration tazarotene PT C0151907
Skin exfoliation tazarotene LLT C0237849
Skin exfoliation tazarotene PT C0237849
Skin exfoliation tazarotene PT C0237849
Skin hyperpigmentation tazarotene LLT C0162834
Skin hyperpigmentation tazarotene PT C0162834
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Tazarotene used for in pharmaceutical contexts?

Tazarotene (CAS 118292-40-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Tazarotene?

Tazarotene has 133 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Application site discolouration, Application site erythema, Skin depigmentation, Application site pain, Skin exfoliation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Tazarotene also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Tazarotene with EU status "restricted".

What clinical phase is Tazarotene in?

Tazarotene is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Tazarotene?

Tazarotene has 7 bioactivity rows in this page query. Rendered target entries include Retinoic acid receptor alpha, Retinoic acid receptor beta, Retinoic acid receptor gamma.